User menu

Chronic lymphocytic leukemia management in the elderly: let us not forget the patient - even on a busy day.

Bibliographic reference Van Den Neste, Eric. Chronic lymphocytic leukemia management in the elderly: let us not forget the patient - even on a busy day.. In: Leukemia and Lymphoma, Vol. 58, no.3, p. 509-510 (2017)
Permanent URL http://hdl.handle.net/2078.1/183423
  1. Geisler C. H., van t' Veer M. B., Jurlander J., Walewski J., Tjonnfjord G., Itala Remes M., Kimby E., Kozak T., Polliack A., Wu K. L., Wittebol S., Abrahamse-Testroote M. C. J., Doorduijn J., Ghidey Alemayehu W., van Oers M. H. J., Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL, 10.1182/blood-2014-01-547737
  2. Vojdeman Fie Juhl, van't Veer Mars B., Tjønnfjord Geir E., Itälä-Remes Maija, Kimby Eva, Polliack Aaron, Wu Ka L., Doorduijn Jeanette K., Alemayehu Wendimagegn G., Wittebol Shulamiet, Kozak Tomas, Walewski Jan, Abrahamse-Testroote Martine C. J., van Oers Marinus H. J., Geisler Christian Hartmann, The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia, 10.1080/10428194.2016.1213831
  3. Lepretre S., Aurran T., Mahe B., Cazin B., Tournilhac O., Maisonneuve H., Casasnovas O., Delmer A., Leblond V., Royer B., Corront B., Chevret S., Delepine R., Vaudaux S., Van Den Neste E., Bene M. C., Letestu R., Cymbalista F., Feugier P., Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial, 10.1182/blood-2011-07-365437
  4. Plackett T. P., Aging and innate immune cells, 10.1189/jlb.1103592
  5. Hasib L., Lundberg A. K., Zachrisson H., Ernerudh J., Jonasson L., Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease, 10.1111/joim.12398
  6. Eichhorst Barbara, Hallek Michael, Goede Valentin, New treatment approaches in CLL: Challenges and opportunities in the elderly, 10.1016/j.jgo.2016.07.007
  7. O'Brien S. M., Lamanna N., Kipps T. J., Flinn I., Zelenetz A. D., Burger J. A., Keating M., Mitra S., Holes L., Yu A. S., Johnson D. M., Miller L. L., Kim Y., Dansey R. D., Dubowy R. L., Coutre S. E., A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia, 10.1182/blood-2015-03-630947
  8. Burger Jan A., Tedeschi Alessandra, Barr Paul M., Robak Tadeusz, Owen Carolyn, Ghia Paolo, Bairey Osnat, Hillmen Peter, Bartlett Nancy L., Li Jianyong, Simpson David, Grosicki Sebastian, Devereux Stephen, McCarthy Helen, Coutre Steven, Quach Hang, Gaidano Gianluca, Maslyak Zvenyslava, Stevens Don A., Janssens Ann, Offner Fritz, Mayer Jiří, O’Dwyer Michael, Hellmann Andrzej, Schuh Anna, Siddiqi Tanya, Polliack Aaron, Tam Constantine S., Suri Deepali, Cheng Mei, Clow Fong, Styles Lori, James Danelle F., Kipps Thomas J., Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, 10.1056/nejmoa1509388